The discovery of IDH1 mutations in human glioma and the recent clinical findings in IDH1- and IDH2-mutant acute myeloid leukemia patients highlights the potential clinical utility of brain-penetrant IDH1 mutant-selective compounds. Here, IDH2 is linked to acute myeloid leukemia.